CliffBio
small molecule

PROTOPIC

TACROLIMUS

Loss of exclusivity—loss of exclusivity
CompanyLEO PHARMA AS

Drug detail

Brand namePROTOPIC
Active ingredientTACROLIMUS
Strength0.03%
Dosage formOINTMENT
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2000
Marketing statusRX

More from LEO PHARMA AS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

PROTOPIC patent cliff — loss of exclusivity — | CliffBio